- Full Year Revenues Increased 10.5% to a Record $983.6 Million Through Market Share Gains, GeographicalExpansion and Increased Demand for Vinyl Products - - Full Year Single-Family Residential Revenue Grew to a Record $403.4 Million - - Record Full Year Gross Profit of $421.4 Million, Representing 42.8% of Revenues - - Full Year Net Income of $159.6 Million, or $3.42 Per Diluted Share; Full Year Adjusted Net Income1 of $167.0 Million, or $3.58 Per Diluted Share - - Full Year Adjusted EBITDA1 of $291.3 Mill ...

KYIV, Ukraine, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Members of the Board of Directors of Kyivstar Group Ltd (“Kyivstar Group”; Nasdaq: KYIV;KYIVW), the parent company of JSC Kyivstar, Ukraine's leading digital operator and part of VEON Group (Nasdaq: VEON), visited the company's headquarters in Kyiv on the fourth anniversary of the full-scale war to meet with Ukrainian employees and reaffirm their unwavering support for Ukraine. VEON Founder Augie K Fabela II, the 70th US Secretary of State Mike Pompeo, Michie ...

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases Strong Balance Sheet Provides Runway to the End of 2028; Cash, Ca ...

– Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 – – Company on track to report ELEVATE-45-201 data from Cohort 1 in mid-2026 – – Independent Data Monitoring Committee recommended initiation of Cohort 2 at the increased dose of 12 mg/kg in the ELEVATE-44-201 study – – Cash runway expected into Q3 2027 with $296 million in cash, cash equivalents and marketable securities as of December 31, 2025 – BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeu ...

-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ---- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA ---- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO in March 2026 -- -- ...

Core Viewpoint - AMG announces the retirement of Karen L. Alvingham from its Board of Directors and the appointment of G. Staley Cates, effective April 1, 2026, highlighting a transition in leadership and continued commitment to long-term value creation [2][4]. Group 1: Board Changes - G. Staley Cates will join AMG's Board of Directors on April 1, 2026, bringing extensive experience from his tenure at Southeastern Asset Management [2][3]. - Karen L. Alvingham, who has served on the Board since January 2018, will retire on the same date, with appreciation expressed for her contributions during a significant growth period for AMG [2][4]. Group 2: Leadership and Strategy - Jay C. Horgen has been re-appointed as President, effective April 1, 2026, and will continue in his role as Chief Executive Officer, indicating stability in leadership [4]. - AMG's strategy focuses on generating long-term value by investing in high-quality independent partner-owned firms, with a reported aggregate assets under management of approximately $813 billion as of December 31, 2025 [5].

Core Insights - Aclaris Therapeutics reported positive interim results from its Phase 1a trials for the bispecific antibody ATI-052, indicating strong safety and tolerability, with complete results expected in Q2 2026 [1][3] - The company has initiated Phase 1b proof-of-concept trials for ATI-052 in atopic dermatitis and asthma, with top line results anticipated in the second half of 2026 [1][2] - Aclaris plans to file an Investigational New Drug (IND) application for its lead ITK inhibitor candidate, ATI-9494, in the second half of 2026 [1][12] Pipeline Developments - Positive interim results from the Phase 1a SAD/MAD trial of ATI-052 showed a favorable safety profile and robust target engagement, supporting potential extended dosing every three months [3][2] - Two Phase 1b POC trials for ATI-052 have been initiated, with results expected in the latter half of 2026 [3][2] - Planning for a Phase 2b program for ATI-052 is underway, targeting asthma and atopic dermatitis as initial indications [3] Financial Performance - Aclaris reported a net loss of $19.8 million for Q4 2025, a significant decrease from a net loss of $96.6 million in Q4 2024 [7] - Total revenue for Q4 2025 was $1.3 million, down from $9.2 million in Q4 2024, primarily due to a prior commercial milestone [8] - Research and development expenses increased to $16.6 million in Q4 2025 from $9.0 million in the prior year, driven by higher costs associated with product candidate development [9] Liquidity and Capital Resources - As of December 31, 2025, Aclaris had cash, cash equivalents, and marketable securities totaling $151.4 million, down from $203.9 million in 2024 [6][20] - The company believes its current financial resources will be sufficient to fund operations into the second half of 2028 [6]

Fourth Quarter HighlightsFourth quarter sales totaled $1.49 billion, up 13.2% driven by acquisitionsCompleted SPI Acquisition Full Year HighlightsCompleted seven acquisitions, adding approximately $1.2 billion in annual salesReturned $434.2 million in capital to stockholders through the repurchase of ~1.4 million shares 2026 OutlookExpects 2026 sales between $5.925 to $6.225 billion andadjusted EBITDA in the range of $1.005 billion to $1.155 billionAcquisitions continue to be top priority for deploying capi ...

Core Insights - Playtika Holding Corp. reported a revenue of $678.8 million for Q4 2025, reflecting a 0.6% increase sequentially and a 4.4% increase year-over-year [9] - Direct-to-Consumer (DTC) revenue reached $250.1 million, marking a 19.5% sequential increase and a 43.2% year-over-year increase [9] - The company experienced a net loss of $(309.3) million, attributed to non-cash impacts from contingent consideration remeasurement related to the SuperPlay acquisition [9][20] - Adjusted net income was reported at $89.0 million, while adjusted EBITDA was $201.4 million, showing a 9.5% year-over-year increase despite a 7.4% sequential decrease [9][34] Q4 2025 Financial Highlights - Revenue for Q4 2025 was $678.8 million, compared to $650.3 million in Q4 2024 [20] - DTC revenue for the quarter was $250.1 million, up from $174.1 million in the previous quarter [9] - Adjusted EBITDA for Q4 2025 was $201.4 million, with an adjusted EBITDA margin of 29.7% [29] FY2025 Financial Highlights - Total revenue for FY2025 was $2,755.4 million, an increase from $2,549.3 million in FY2024 [9] - DTC revenue for FY2025 was $814.5 million, compared to $694.2 million in FY2024 [9] - The company reported a net loss of $(206.4) million for FY2025, a decline from a net income of $162.2 million in FY2024 [9] Operational Metrics - Average Daily Paying Users (DPUs) increased to 357 thousand, a 0.8% sequential increase and a 5.3% year-over-year increase [10] - Average Payer Conversion improved to 4.5%, up from 4.3% in Q3 2025 and 4.2% in Q4 2024 [10] Capital Allocation Framework - The company updated its capital allocation framework, suspending its quarterly dividend to prioritize high-return uses of capital while maintaining buybacks [6] Financial Outlook - For FY2026, Playtika expects revenue to be between $2.70 billion and $2.80 billion, with adjusted EBITDA projected between $730 million and $770 million [7]

Core Viewpoint - Enovis Corporation reported its financial results for Q4 and the full year of 2025, highlighting a net sales growth but significant losses due to goodwill impairment charges. Financial Results Summary Fourth Quarter 2025 - Net sales reached $576 million, reflecting a 3% increase on a reported basis and 2% on an organic basis compared to Q4 2024 [2] - The Global Reconstructive segment saw a 7% increase in net sales on a reported basis, with 3% organic growth, while the Prevention & Recovery segment experienced a 1% decline on a reported basis and remained flat organically [2] - The company reported a net loss from continuing operations of $519 million, which included a non-cash goodwill impairment charge of $501 million [3][4] - Adjusted EBITDA for the quarter was $112 million [3] Full Year 2025 - Total net sales for the year amounted to $2.2 billion, marking a 7% increase on a reported basis and 6% on an organic basis [5] - The Reconstructive segment grew by 10% on a reported basis and 8% organically, while the Prevention & Recovery segment grew by 4% on both bases [5] - The full year net loss from continuing operations was $1,182 million, which included a non-cash goodwill impairment charge of $1,050 million [6] - Adjusted EBITDA for the full year was reported at $403 million [6] Management Commentary - The CEO of Enovis stated that 2025 was a year of meaningful operational progress, with advancements in integration priorities and above-market organic growth [7] - The company aims to maintain a disciplined focus on commercial execution, innovation, operational efficiency, and financial discipline as it moves into 2026 [8] 2026 Financial Outlook - Enovis expects revenue for 2026 to be in the range of $2.31 to $2.37 billion, reflecting 4-6% organic revenue growth [8] - Adjusted EBITDA is anticipated to be between $425 million and $435 million, with adjusted earnings per share projected to be between $3.52 and $3.73 [8]